These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 32780893)

  • 1. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.
    De Flora S; Balansky R; La Maestra S
    FASEB J; 2020 Oct; 34(10):13185-13193. PubMed ID: 32780893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Where are we with the use of N-acetylcysteine as a preventive and adjuvant treatment for COVID-19?
    Di Marco F; Foti G; Corsico AG
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):715-721. PubMed ID: 35113447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral high-dose acetylcysteine: Effective against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)?
    Chen G; Lu H
    Drug Discov Ther; 2022 Jul; 16(3):139-141. PubMed ID: 35527020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.
    Poe FL; Corn J
    Med Hypotheses; 2020 Oct; 143():109862. PubMed ID: 32504923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D and COVID-19: A review on the role of vitamin D in preventing and reducing the severity of COVID-19 infection.
    Abdrabbo M; Birch CM; Brandt M; Cicigoi KA; Coffey SJ; Dolan CC; Dvorak H; Gehrke AC; Gerzema AEL; Hansen A; Henseler EJ; Huelsbeck AC; LaBerge B; Leavens CM; Le CN; Lindquist AC; Ludwig RK; Reynolds JH; Severson NJ; Sherman BA; Sillman HW; Smith MA; Smith MA; Snortheim MJ; Svaren LM; Vanderpas EC; Wackett MJ; Wozney AJ; Bhattacharyya S; Hati S
    Protein Sci; 2021 Nov; 30(11):2206-2220. PubMed ID: 34558135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Thiols in the Treatment of COVID-19: Current Evidence.
    Cazzola M; Rogliani P; Salvi SS; Ora J; Matera MG
    Lung; 2021 Aug; 199(4):335-343. PubMed ID: 34448938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions.
    Izquierdo-Alonso JL; Pérez-Rial S; Rivera CG; Peces-Barba G
    J Infect Public Health; 2022 Dec; 15(12):1477-1483. PubMed ID: 36410267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylcysteine as a potential treatment for COVID-19.
    Jorge-Aarón RM; Rosa-Ester MP
    Future Microbiol; 2020 Jul; 15():959-962. PubMed ID: 32662664
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanics Insights of Alpha-Lipoic Acid against Cardiovascular Diseases during COVID-19 Infection.
    Rochette L; Ghibu S
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A minireview on N-acetylcysteine: An old drug with new approaches.
    Elbini Dhouib I; Jallouli M; Annabi A; Gharbi N; Elfazaa S; Lasram MM
    Life Sci; 2016 Apr; 151():359-363. PubMed ID: 26946308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential Mechanism of N-acetylcysteine in Treating COVID-19.
    Zhou N; Yang X; Huang A; Chen Z
    Curr Pharm Biotechnol; 2021; 22(12):1584-1590. PubMed ID: 33371832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.
    Mohanty RR; Padhy BM; Das S; Meher BR
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2802-2807. PubMed ID: 33829465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress.
    Raghu G; Berk M; Campochiaro PA; Jaeschke H; Marenzi G; Richeldi L; Wen FQ; Nicoletti F; Calverley PMA
    Curr Neuropharmacol; 2021; 19(8):1202-1224. PubMed ID: 33380301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review.
    Suhail S; Zajac J; Fossum C; Lowater H; McCracken C; Severson N; Laatsch B; Narkiewicz-Jodko A; Johnson B; Liebau J; Bhattacharyya S; Hati S
    Protein J; 2020 Dec; 39(6):644-656. PubMed ID: 33106987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidation pathway and exacerbations in COPD: the role of NAC.
    Matera MG; Calzetta L; Cazzola M
    Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetycysteine: A potential therapeutic agent in COVID-19 infection.
    Jaiswal N; Bhatnagar M; Shah H
    Med Hypotheses; 2020 Nov; 144():110133. PubMed ID: 32758904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the Cell Uptake of Delta and Omicron SARS-CoV-2 Pseudoviruses by
    La Maestra S; Garibaldi S; Balansky R; D'Agostini F; Micale RT; De Flora S
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manipulation of ACE2 expression in COVID-19.
    Chaudhry F; Lavandero S; Xie X; Sabharwal B; Zheng YY; Correa A; Narula J; Levy P
    Open Heart; 2020 Dec; 7(2):. PubMed ID: 33443121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.